BioAge Labs, Inc. (NASDAQ:BIOA) Sees Large Growth in Short Interest

BioAge Labs, Inc. (NASDAQ:BIOA) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,744,445 shares, a growth of 87.9% from the June 15th total of 1,992,676 shares. Currently, 10.6% of the company’s stock are sold short. Based on an average daily trading volume, of 932,909 shares, the short-interest ratio is presently 4.0 days.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. BTIG Research started coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price on the stock. Roth Capital began coverage on BioAge Labs in a report on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target for the company. Needham & Company LLC started coverage on BioAge Labs in a research report on Friday, March 27th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

BioAge Labs Stock Up 5.7%

Shares of BioAge Labs stock traded up $1.26 on Friday, reaching $23.42. The company’s stock had a trading volume of 51,852 shares, compared to its average volume of 609,561. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -9.65 and a beta of 0.61. The firm’s fifty day simple moving average is $19.78 and its two-hundred day simple moving average is $18.99. BioAge Labs has a 52 week low of $4.11 and a 52 week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. As a group, research analysts predict that BioAge Labs will post -2.68 EPS for the current year.

Institutional Trading of BioAge Labs

Several large investors have recently added to or reduced their stakes in BIOA. Janus Henderson Group PLC lifted its position in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after purchasing an additional 1,685,063 shares in the last quarter. Octagon Capital Advisors LP grew its holdings in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares during the period. Vanguard Group Inc. increased its position in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of BioAge Labs in the fourth quarter worth about $13,892,000. Finally, Geode Capital Management LLC raised its stake in shares of BioAge Labs by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after buying an additional 28,646 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.